Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 3/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 8/20 | 0.35 |
| ▸ | ESR1 | P03372 | 7/20 | 0.35 |
| ▸ | AR | P10275 | 7/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.32 |
| ▸ | SHBG | P04278 | 1/20 | 0.30 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL513011 | 0.82 | L3MBTL1 (0.36) | SRD5A2ESR2ESR1ARCYP19A1 | |
| SCHEMBL511826 | 0.81 | ESR2 (0.36) | SRD5A2ESR2ESR1ARCYP19A1 | |
| SCHEMBL5570856 | 0.74 | CYP19A1 (0.43) | SRD5A2ESR2ESR1ARCYP19A1 | |
| SCHEMBL5574814 | 0.73 | L3MBTL1 (0.38) | SRD5A2ESR2ESR1ARCYP19A1 | |
| SCHEMBL5572192 | 0.73 | L3MBTL1 (0.38) | SRD5A2ESR2ESR1ARCYP19A1 | |
| SCHEMBL512337 | 0.72 | CYP19A1 (0.36) | SRD5A2ARCYP19A1L3MBTL1SRD5A1 | |
| SCHEMBL512336 | 0.72 | CYP19A1 (0.36) | SRD5A2ARCYP19A1L3MBTL1SRD5A1 | |
| SCHEMBL4305112 | 0.72 | L3MBTL1 (0.42) | SRD5A2ESR2ESR1ARCYP19A1 | |
| SCHEMBL4310477 | 0.72 | L3MBTL1 (0.42) | SRD5A2ESR2ESR1ARCYP19A1 | |
| SCHEMBL1418909 | 0.72 | L3MBTL1 (0.42) | SRD5A2ESR2ESR1ARCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1807118-A2 | STEROID ANALOGS AND CHARACTERIZATION AND TREATMENT METHODS | Hollis-Eden Pharmaceuticals Inc. (US) | 2007-07-18 | — | — | EP | disclosed |
| WO-2007030124-A2 | TREATMENT SCREENING METHODS | HOLLIS-EDEN PHARMACEUTICALS, INC (US) | 2007-03-15 | — | — | WO | disclosed |
| WO-2006110172-A2 | STEROID ANALOGS AND CHARACTERIZATION AND TREATMENT METHODS | HOLLIS-EDEN PHARMACEUTICALS.INC. (US) | 2006-10-19 | — | — | WO | disclosed |